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Three-dimensional (3D) microphysiological systems (MPSs) mimicking human organ
function in vitro are an emerging alternative to conventional monolayer cell culture and
animal models for drug development. Human induced pluripotent stem cells (hiPSCs) have
the potential to capture the diversity of human genetics and provide an unlimited supply of
cells. Combining hiPSCswith microfluidics technology in MPSs offers new perspectives for
drug development. Here, the integration of a newly developed liver MPS with a cardiac
MPS—both created with the same hiPSC line—to study drug–drug interaction (DDI) is
reported. As a prominent example of clinically relevant DDI, the interaction of the
arrhythmogenic gastroprokinetic cisapride with the fungicide ketoconazole was
investigated. As seen in patients, metabolic conversion of cisapride to non-
arrhythmogenic norcisapride in the liver MPS by the cytochrome P450 enzyme
CYP3A4 was inhibited by ketoconazole, leading to arrhythmia in the cardiac MPS.
These results establish integration of hiPSC-based liver and cardiac MPSs to facilitate
screening for DDI, and thus drug efficacy and toxicity, isogenic in the same genetic
background.
Keywords: drug–drug interaction, microphysiological systems, liver and heart integration, ketoconazole, cisapride,
hiPSC-derived cells
INTRODUCTION
The drug development pipeline generally starts with a broad collection of candidate compounds that
are narrowed down by traditional in vitro drug screening tools including biochemical analysis and
cell-based assays, for example, using immortalized cell lines, computational modeling, and then
testing in animal models. The successful compounds are then tested in human preclinical and clinical
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screening to market are estimated at more than 2.5 billion USD
(Herper, 2013; DiMasi et al., 2016) and can take ∼10–15 years
(Mathur et al., 2013; Mathur et al., 2015). One of the more costly
and inefficient steps in this process is the clinical trial phase
(ASPE, 2018). Too often compounds pass the go/no-go risk
decisions based on animal model data, but fail later in clinical
trials due to species-specific differences in physiology. The worst-
case scenario occurs when drugs make it through the full
screening pipeline and clinical trials to market, only to be
recalled due to unforeseen side effects in some patients, a
prominent example being the arrhythmogenic effect of the
gastroprokinetic cisapride (Okada et al., 2015). In addition to
the inability of animal models to accurately mimic human
physiology, such failures are due to lack of diversity in the
human genetic backgrounds tested in single cell lines, and lack
of diversity in phase I and II clinical trials.
Drug-induced liver injury (DILI) and cardiotoxicity are the
leading causes of preclinical and clinical withdrawals of marketed
pharmaceuticals due to safety issues (Kaplowitz, 2005; Guo et al.,
2011; Craveiro et al., 2020), and manifest as serious
complications, including hepatitis and liver cell death,
potentially leading to liver failure, and cardiac arrhythmia
(Abboud and Kaplowitz, 2007; Ewer and Ewer, 2015). The
human liver is especially significant for toxicity as it is the first
stop for most compounds after they enter the body for initial drug
metabolism before subsequent uptake by other organs (The
International Transporter Consortium, 2010). Animal models
perform variably in representing human diseases and predicting
toxicity to humans due to inter-species differences in drug
absorption, distribution, metabolism, excretion, and/or toxicity
(ADME/Tox) (Jianling and Suzanne, 2009; Scott et al., 2013;
Proctor et al., 2017). Accordingly, the risk of human DILI is not
well predicted by animal models. Additionally, animal studies can
only partially recapitulate patient-specific factors such as genetics,
age, environment, and concomitant diseases (Olson et al., 2000).
The limitation of animal models to predict DILI has led to the
development of in vitro liver models; however, current versions
have limitations, most notably due to the complexity of the liver,
which performs more than 500 functions, including metabolic,
synthetic, immunologic, and detoxification processes (Taub,
2004). The most commonly used models of liver toxicity
involve two-dimensional (2D) monolayer cultures of primary
human hepatocytes (pHeps). They currently represent the
standard for drug screening, toxicology studies, cell-based
therapies, and in vitro disease modeling. Indeed, they
recapitulate most liver functions and represent diverse human
genetic disease backgrounds that are not captured by single
human cancer cell lines. pHeps also bypass ethical concerns
regarding refined and reduced use of animal experiments.
However, there are still substantial problems using pHeps.
One of the limitations is the difficulty to perform long-term
cultures (≥7 days) due to the propensity of pHeps to
dedifferentiate in vitro within a few days, causing them to lose
hepatocyte-specific functions (Hewitt et al., 2007; Rowe et al.,
2013) and no longer accurately represent the biology of the liver.
Co-cultures of pHeps with endothelial cells and/or fibroblasts, as
well as recent advances in long-term cultures of pHeps, might
overcome these limitations (Nahmias et al., 2006; Xiang et al.,
2019), but not the shortage of donor livers (Fraczek et al., 2013;
Griffith et al., 2014), resulting in high cost and considerable
genetic and functional variation of commercial pHeps (Bhushan
et al., 2016). These variations alone make interlaboratory
comparisons nearly impossible. Taken together, conventional
2D monolayer cultures using pHeps are often too simplified,
ultimately failing to adequately predict DILI, putting human lives
at risk and wasting valuable resources for pharmaceutical
companies during clinical drug development.
Human induced pluripotent stem cell (hiPSC)-derived
hepatocytes (hiPSC-Heps) have the potential to overcome the
limitations of pHeps and human cell lines. hiPSCs are pluripotent
cells generated by reprogramming of mature somatic cells, for
example, adult human fibroblasts, by overexpression of the
Yamanaka factors (Takahashi and Yamanaka, 2006; Takahashi
et al., 2007). hiPSCs can provide a virtually inexhaustible source
of cells from different genotypes, including healthy or disease-
specific cells (Si-Tayeb et al., 2010; Hannan et al., 2013). By
providing a renewable source of cells that maintain the genotype
of the donor, hiPSCs reduce cell source variability and facilitate
an unlimited number of trials of patient-specific drug screening at
the early stage of the development pipeline (Liu et al., 2010; Choi
et al., 2011; Liu et al., 2011; Mi et al., 2013). However, like other
protocols for directed differentiation of hiPSCs, current
differentiation protocols for hiPSC-Heps produce immature
cells that lack certain functions of pHeps (Shan et al., 2013;
Avior et al., 2015).
Although pHeps and hiPSC-Heps are widely used in 2D
monolayer culture for initial assessment of drug metabolism,
these monocultures do not provide 3D organization, non-
parenchymal cells, structural cell–cell interactions, nor their
associated paracrine interactions (Bale et al., 2014). Advances
in 2D co-culture (e.g., of hiPSC-Heps and fibroblasts)
exploiting micropatterned architecture have shown
promising results predicting DILI (Berger et al., 2014).
Compared to 2D, bioinspired 3D in vitro systems provide
more structural organization, which is beneficial to
maintaining cell differentiation and maturity (Gieseck et al.,
2014; Ardalani et al., 2019). For example, 3D culture can reverse
or prevent dedifferentiation of pHeps (Dunn et al., 1991; Dash
et al., 2009) and promote metabolic enzyme functionality
comparable to in vivo levels for adult rat hepatocytes
(Tuschl et al., 2009; Ebrahimkhani et al., 2014; Proctor et al.,
2017). Thus, the combination of hiPSCs and 3D culture offers
great potential to improve the efficiency and efficacy of the drug
development pipeline by allowing to study hepatocytes in a
more biologically relevant setting (Dalgetty et al., 2009; Fabre
et al., 2014; Kyungsuk et al., 2014; Moradi et al., 2020).
However, only few published studies used hiPSC-Heps to
build 3D liver MPSs (Bale et al., 2014; Mun et al., 2019;
Bircsak et al., 2021).
Another challenge in the study of DDI is inter-organ cross
talk. Specifically, liver metabolism is a key modulator of drug
toxicity in various other organs. Several recent studies have
tackled the challenge of linking liver models to other organ
and tissue models (Lee and Sung, 2018; Boeri et al., 2019;
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Baert et al., 2020; Pires de Mello et al., 2020). Since cardiotoxicity
is the most common cause for safety-related market withdrawal,
in this study we focused on heart–liver cross talk as one clinically
relevant organ pair. Liver and heart models have been linked by a
few research groups in recent years (Zhang et al., 2017; Oleaga
et al., 2018; McAleer et al., 2019; Pires de Mello et al., 2020);
however, in these combination platforms the individual tissue
models were either 2D monolayer cultures (Zhang et al., 2017;
McAleer et al., 2019; Pires de Mello et al., 2020), very simple
organoids (Zhang et al., 2017), or genetically distinct (Zhang
et al., 2017; Oleaga et al., 2018; McAleer et al., 2019; Pires deMello
et al., 2020). We and others have demonstrated that 3D liver and
cardiac MPS are functionally superior to conventional 2D
monolayer cultures (Bale et al., 2014; Mathur et al., 2015;
Prodanov et al., 2016; Schepers et al., 2016; Du et al., 2017;
Lee-Montiel et al., 2017; Huebsch et al., 2018). To date, an
integrated liver–heart MPS generated with cells derived from a
single donor has not been reported.
In our study, we present the first use of a 3D hiPSC-based
in vitro liver model on a microfabricated platform, that is, MPS
(also known as “organ-on-a-chip” or “tissue chip”), functionally
coupled with a 3D hiPSC-based cardiac MPS platform (Mathur
et al., 2015; Huebsch et al., 2018; Tveito et al., 2018). Moreover,
the use of isogenic hiPSCs allowed us to produce different 3D
tissues—liver and heart—from the same donor and thus with
identical genetic background. In addition, we modified our
recently reported protocol (Zhu et al., 2014) to produce
hiPSC-Heps suitable for studies of drug metabolism, including
sufficient cytochrome P450 (CYP) 3A4 activity and long-term
function in the MPS. As an example of clinically relevant DDI, we
focused on cisapride, a gastroprokinetic intended to treat the
symptoms of heartburn in adults (Wiseman and Faulds, 1994).
This drug causes prolongation of the QT interval, ventricular
arrhythmias, and torsade de pointes (Wysowski and Bacsanyi,
1996) in patients taking medications that interfere with cisapride
metabolism or prolong the QT interval. In 2000, cisapride was
removed from the US market as a result of 80 deaths and 341
incidents of arrhythmias, including 107 episodes of torsade de
pointes, reported to the FDA from 1993 to 1999 (Wysowski et al.,
2001; Shah, 2002). To functionally connect the liver and cardiac
MPSs, we developed a common medium for survival and
function of each tissue. By correctly predicting CYP3A4-
dependent DDI between cisapride and the antifungal
ketoconazole, we show that MPS technologies are effective for
predicting drug efficacy and toxicity across multiple organs, and




The hiPSC line WTC was generated by reprogramming of skin
fibroblasts derived from a healthy 30-year-old Japanese adult
male with no known family history of heart disease,
generously provided by Prof. Bruce Conklin (Gladstone
Institutes) and available from the Coriell Repository
(#GM25256). WTC was used for the generation of hiPSC-
Heps. hiPSC-derived cardiomyocytes were generated from
WTC edited to harbor a single copy of CAG-driven
GCaMP6f knocked into the first exon of the AAVS1 “safe
harbor” locus (Huebsch et al., 2015). For experiments with
pHeps, commercially available cryopreserved cells from
ThermoFisher Scientific (lot#Hu8138) were used.
Differentiation of Human Induced
Pluripotent Stem Cell-Heps
Differentiation of hiPSCs (day 0) into hiPSC-Heps (days 23–25)
was performed according to an optimized protocol. The cells were
cultured on Cultrex Basement Membrane Extract (BME)
(Trevigen) diluted 40 times in Knockout DMEM
(ThermoFisher Scientific) for the entire hepatocyte
differentiation process. At day 0, hiPSCs were split and kept in
mTESR (Stem Cell Technologies) supplemented with 10 µM
Rock inhibitor (Tocris Bioscience) to form a confluent layer of
hiPSCs on day 1 when the hepatocyte differentiation was
initiated. From days 1 to 7, RPMI 1640 medium
(ThermoFisher Scientific) was used and supplemented with
standard antibiotics and antimycotics and recombinant human
Activin A (PeproTech EC) at 100 ng/ml. Between days 2 and 7,
Gem21 NeuroPlex without Insulin (Gemini BioProducts),
nonessential amino acids (ThermoFisher Scientific), and
sodium butyrate (Sigma Aldrich) at 500 µM was added.
KnockOut Serum Replacement (ThermoFisher Scientific) was
added to the differentiation medium from days 1 to 3 in
decreasing amounts of 2, 1, and 0.2%, respectively. The small
molecules CHIR 99021 (Tocris Bioscience) at 3 µM and PI-103
(Selleckchem) at 50 nM were added at day 1 and from days 1 to 3,
respectively. From day 8, the cells were cultured in IMDM
(ThermoFischer Scientific) supplemented with standard
antibiotics and antimycotics, Gem21 NeuroPlex without
Insulin (Gemini BioProducts); 100 nM insulin, 100 nM
dexamethasone, and 400 µM monothioglycerol (all Sigma
Aldrich); nonessential amino acids; and human FGF2 at
10 ng/ml and human BMP4 at 20 ng/ml (both Peprotech)
until day 18. At day 13, HGF (Peprotech) at 20 ng/ml was
added until the end of the hepatocyte differentiation. From
day 18 onward, the cells were cultured in Hepatocyte Basal
Medium (Lonza CC-3199) supplemented with all the
components of Hepatocyte Culture Medium SingleQuots
except EGF (Lonza CC-4182 containing gentamicin-
amphotericin, transferrin, insulin, hydrocortisone, and fatty
acid–free bovine serum albumin). This medium is referred to
as hepatocyte culture medium (HCM).
Immunofluorescence in Conventional Cell
Culture and Liver Microphysiological
System
In conventional cell culture, hiPSCs and hiPSC-Heps were fixed
for 20 min at room temperature (RT) in 4% paraformaldehyde
(PFA) and washed three times with phosphate-buffered saline
(PBS). The cells were blocked for 1 h with 3% BSA and
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permeabilized with 0.3% Triton X-100 (Sigma). The cells were
labeled with rabbit anti-OCT3/4 antibody (sc-9081; SantaCruz
Biotechnology) diluted 1:500, goat anti-HNF4 antibody (sc-6557;
SantaCruz Biotechnology) diluted 1:500, goat antihuman
albumin antibody (A80–129A; Bethyl Laboratories) diluted 1:
500, mouse anti–alpha-fetoprotein (MA1-19342; Invitrogen)
diluted 1:500, and DAPI (D1306; Invitrogen) for nuclear
staining. The secondary antibodies were Alexa Fluor 488/555
donkey-anti-rabbit or anti-goat or anti-mouse IgG diluted 1:
1,000 (Invitrogen). The cells were imaged using a Nikon
Eclipse TE300 with a Lumencore Spectra X light engine. The
liver MPS was washed with PBS and fixed at RT for 30 min with
4% PFA using a 3D collagen gel-staining protocol and washed
three times with PBS. After permeabilization in 1% Triton X-100
(Sigma) for 30 min, the cells were incubated for ∼24 h at 4°C with
the same primary antibodies as above but at different
concentrations: Both goat antihuman albumin and mouse
anti–alpha-fetoprotein were diluted 1:100. Secondary
antibodies with fluorescent probes Alexa 488 (A-11055;
Invitrogen) and R-PE 565 (P21129; Invitrogen) were incubated
at 4°C for 6 h and washed three times for 5 min with cold PBS.
The liver MPS was imaged by confocal microscopy. The confocal
images were collected using a Carl Zeiss LSM 710 confocal
microscope equipped with a plan-apochromat 10 Å∼/0.45
objective.
Flow Cytometry
At day 23 of differentiation, hiPSC-Heps were digested with
1 mg/ml collagenase for 20 min to singularize cells. The cells
were then fixed with 4% PFA for 20 min at RT and labeled with
the following antibodies: Antihuman albumin (A80–129A; Bethyl
Laboratories) detected with a secondary antibody conjugated
with Alexa Flour-488 (Life Technologies) and anti-ASGR1
(8D7 clone conjugated with PE; BD Biosciences). Albumin
and ASGR1-positive cell populations were determined by flow
cytometry analysis with an Attune NxT Acoustic Focusing
Cytometer (Thermo Fisher Scientific). FlowJo software was
used to analyze the data.
Drug Transport Study
Cells were washed with carbogenated Williams’ E (Gibco;
A1217601) (adjusted pH 7.4 at 37°C) for 15 min at 37°C
before transport or metabolism studies. The drug uptake
transport study was initiated by adding each transporter
substrate with or without its inhibitor in Williams’ E
medium, and incubation at 37°C for 2 min in a shaker-
incubator. The reaction was terminated by removing the dose
solution followed by washing the cells three times with ice-cold
PBS. The following substrates and inhibitors were used: 10 µM
acyclovir (including 0.1 µCi [3H]-acyclovir, OAT substrate) and
1 mM probenecid (OAT inhibitor) for the OAT transport study,
1 mM metformin (including 1 µCi [14C]-metformin, OCT
substrate) and 1 µM decynium-22 (OCT inhibitor) for the
OCT transport study, and 10 µM rosuvastatin (including
0.25 µCi [3H]-rosuvastatin, OATP substrate) and 50 µM
rifamycin-SV (OATP inhibitor) for the OATP transport
study. Cells were harvested for further drug analysis. The
drug efflux transport study was initiated by adding each
transport substrate with or without its inhibitor in Williams’
E medium and incubation at 37°C for 15 min in a shaker-
incubator. The reaction was terminated by removing the dose
solution followed by washing cells three times with ice-cold PBS.
The following substrates and inhibitors were used: 10 µM
digoxin (including 0.25 µCi [3H]-digoxin, P-gp substrate) and
10 µM GG918 (P-gp inhibitor) for the P-gp transport study and
10 µM of mitoxantrone (including 1 µCi [3H]-mitoxantrone,
BCRP substrate) and 5 µM GG918 (BCRP inhibitor) for the
BCRP transport study. Cells were harvested for further drug
analysis (see “Drug Metabolism Measurements” section).
Cytochrome P450 Luciferase Activity Assay
CYP activity was assessed using the luciferin-based P450-Glo
assays (Promega). Cells were washed with basal HCM for 15 min
prior to incubation with CYP substrates at the following
concentrations: 100 μM for 1A2, 100 μM for 2C9, 10 μM for
2C19, 30 μM for 2D6, 3 μM for 3A4, and 150 μM for 3A7. Cells
were incubated with substrates for 3.5 h except for the 3A4 assay
that was incubated for 70 min. At the end of the incubation
period, 50 µL supernatant was transferred into a 96-well plate in
technical triplicates, and 50 µL of CYP-specific detection reagent
was added to each well. The plate was covered in foil and mixed
gently for 20 min, and absorbance was measured at 450 nm on a
plate reader (SpectraMax i3, Molecular Devices). Samples
included a negative control consisting of HCM only (no cells)
that was used for background correction.
Drug Metabolism Enzymatic Assays
Each enzyme substrate was dissolved in Williams’ E medium and
incubated at 37°C in a shaker-incubator. For metabolism studies
of UGTs and SULTs, the cells were incubated with 10 µM 1-
naphthol or 10 µM nitrophenol (Sigma-Aldrich), respectively, for
15 min at 37°C. Then the dosing solution was collected; the cells
were washed three times with ice-cold PBS and harvested for
further drug analysis (see “Drug Metabolism Measurements”
section).
Quantitative Polymerase Chain Reaction
RNA was extracted from hiPSC-Heps and pHeps by the Trizol/
chloroform method. Each sample was suspended in 500 µL of
Trizol to which 100 µL (1 V:5 V) of chloroform was added. After
15 s of vortexing and 5 min of incubation at RT, the samples were
centrifuged for 5 min at 12,000 rpm. The upper phase containing
RNA was transferred into a new Eppendorf tube. Isopropanol
(1 V:1 V) was added to each tube and slowly inverted five times.
The samples were centrifuged for 10 min at 12,000 rpm at 4°C.
The RNA pellet was kept on ice until the end of the procedure.
The pellet was washed twice in 750 µL of 70% ethanol and air-
dried on ice. The pellet was resuspended in an appropriate
volume of nuclease-free water and the RNA concentration was
determined on a Nanodrop (ThermoFisher Scientific). The
reverse transcription was performed with 1 μg of RNA
template using cDNA Supermix (Quanta Biosciences) and
nuclease-free water in a final volume of 20 μl. qPCR was
performed on 100 ng of cDNA using SYBR Green Supermix
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(Affymetrix) and specific primers on an Applied Biosciences
ViiA7 Real-Time PCR System (Invitrogen).
Computational Modeling
Laminar fluid flow and dilute species transport in the liver MPS
was simulated using COMSOL Multiphysics® 5.3a (COMSOL
AB). Laminar fluid flow was governed by the Navier–Stokes
equations and dilute species (oxygen (O2) and a generic small
molecule) transport by the advection–diffusion equation, both
solved in COMSOL® subject to the following boundary
conditions: no-slip on all media channel walls and membrane
surfaces; laminar inflow rate specified at the media channel inlet;
laminar outflow conditions at the outlet; and dilute species
concentration specified at the inlet. O2 diffusion through the
3.5-mm-thick PDMS slab was also simulated in COMSOL®,
subjected to ambient O2 concentration at the top of the slab
and O2 partial pressure continuity at the media channel and
cell chamber walls. In our simulations, fluid (media with
supplements) with a density of 1,000 kg/m3 and a dynamic
viscosity of 0.78mPa·s at 37°C (Bacabac et al., 2005; Mathur
et al., 2015) was used. Flow across the 15-μm-thick porous
membrane was neglected since low membrane porosity (5.6%),
small membrane pore size (mean pore diameter 3 μm), and
cultured cells on the cell chamber side of the membrane resulted
in flow resistances through the membrane that were orders of
magnitude higher than through the media channel (height 100 μm)
(Loskill et al., 2017). Moreover, the cultured cells within the cell
chamber increased flow resistance there. Thus, it was assumed that
there was no media flow into or within the cell chamber so that
dilute species transport within the cell chamber was by diffusion
only (Loskill et al., 2017). Small flows within cell culture chambers
in membrane bilayer microfluidic devices have been considered
elsewhere (Inamdar and Borenstein, 2011; Inamdar et al., 2011).
Three sets of COMSOL® simulations were conducted. In the
first set, the transport of a generic small molecule within culture
media in the liverMPSwasmodeled at an inlet flow rate of 20 μl/h,
an inlet concentration of 1 mol/m3, zero initial concentration in
the device, a diffusion coefficient of 1.0 × 10−9 m2/s in culture
media, and no cell uptake and no flux through walls. The second
and third sets of simulations involved O2 transport, diffusion, and
uptake. The media channel inlet and initial media channel and cell
chamber O2 concentrations were 0.173 mol/m
3, which is the
saturation level in culture media at 37°C in equilibrium with
ambient incubator air at 37°C, 1 atmosphere (atm) pressure, with
18.7% O2 (21% O2 in dry air reduced by 5% CO2 and 6% water
vapor). On the PDMS surfaces exposed to ambient incubator air,
the O2 concentration in the PDMS was 1.11 mM, the saturation
level. The diffusion coefficients of O2 in PDMS and culture media
were 3.25 × 10−9 m2/s and 3.0 × 10−9 m2/s, respectively
(Buchwald, 2009; Markov et al., 2014; Mathur et al., 2015).
Cell O2 consumption was modeled by the Michaelis–Menten
kinetics with rate  −VO2max • ρcell • c/(Km • Scell + c), where
c was the local O2 concentration, Km  5.6 mmHg was the
Michaelis–Menten constant (Allen and Bhatia, 2003; Kim
et al., 2013), and Scell  1.049 mM/(atm O2) was the solubility
of O2 in cells (Chakraborty et al., 2007; Kim et al., 2013). VO2max 
1.04 × 10−16 mol/s/cell was measured for hiPSC-Heps using the
Seahorse XF24 cellular respirometer (Agilent) (see the Oxygen
Consumption Rate section for details). A cell density in the cell
chamber of ρcell  6.44 × 1013 cells/m3 based on ∼ 10,000 (9,812 ±
838) cells was assumed per liver chip.
Liver Microphysiological System
Fabrication and Design Dimensions
The liver MPS was designed to mimic a ∼100 parallel circuit of
liver sinusoids (∼6–15 μm in width) (Braet and Wisse, 2002;
Vollmar and Menger, 2009). The design consisted of a
rectangular chamber divided by a PET membrane to mimic
the fenestrations present in the sinusoidal endothelial cells in
the human liver (Horn et al., 1987). The liver MPS was composed
of two chambers with the following dimensions: 5,560 μm
(length) × 560 μm (width) × 100 μm (height) for the cell
chamber side, and in the media channel the volume was
0.32 μL. The total volume of the chip was empirically
measured to account for the cell inlet and the media outlet
having a total volume of 2 μL. Computational modeling (see
the previous section) was used to verify the chip dimensions and
fluidic design was adequate for the transport of O2 and drugs.
The dual chamber microfluidic device was fabricated using
replica molding from photolithographically defined SU-8masters
on silicon wafers. Briefly, 30 g (top layer) and 6 g (bottom layer)
of PDMS was poured into two silicon wafer masters and baked at
80°C for 8 h, after which O2 plasma was used to bond PDMS
devices to the PETmembrane with 3 μm pore size (Sabeu GmbH)
and the cover glass. To adhere to the PET membranes, they were
treated with bis [3-(trimethoxysilyl)propyl]amine silane and then
rendered hydrophilic (protocol modified from Sip and Folch
(2014) and Loskill et al. (2017)). This treatment also allows for
PET to remain bonded even in the presence of salt-containing
media. The PET membranes were prepared by first being cut into
slightly larger rectangle shapes than those of the individual cell or
media layer patterns and then cleaned in isopropyl alcohol for
10 min. The membranes were then suspended in a plasma
chamber that was filled with 20% O2 and exposed to plasma
at 60W for 60 s. The power source used was a PE-1000 AC
Plasma power source. The membranes were then incubated in a
solution of 97% isopropyl alcohol, 2% bis(3-(trimethoxysilil)
propyl)amine, and 1% H2O at 80°C for 20 min. Following the
incubation, the membranes were rinsed with isopropyl alcohol
and dried at 80°C for 30 min. Following drying (curing), the
membranes were individually placed in 2 ml of 70% ethanol in
type I ASTM laboratory reagent grade H2O for 30 min to render
the membrane hydrophilic.
Liver Microphysiological System Loading
With Human Induced Pluripotent Stem
Cell-Heps
Prior to cell loading, the MPS was sterilized by UV light for
30 min, coated with 100 μg/ml human fibronectin (Corning,
United States) and 100 μg/ml rat tail collagen, type I (Corning,
United States) in PBS, and the interior of the device was dried
under vacuum for 30 s. hiPSC-Heps were trypsinized for
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8–10 min and quenched using 80% DMEM/F12 (Thermofisher,
Carlsbad, CA) with 20% FBS, pelleted at 50 g for 5 min, and then
resuspended at 11 × 106 hepatocytes/mL in HCM supplemented
with 10% fetal bovine serum (Cellgro) and 10 µM Rock inhibitor.
hiPSC-Heps were then pipetted into the cell inlet port of the
device and centrifuged in a bucket at 300 × g for 3 min for optimal
cell loading. The seeded devices were incubated overnight at 37°C
to enhance the formation of a 3D organization. Plating media was
removed from the device and HCM was added and incubated for
24 h at 37°C to allow stabilization of the model before initiating a
10 μL/h flow perfusion using a syringe pump (New Era NE-1800).
To quantify the number of total cells in the liver MPS, the
confocal images of cell nuclei stained with DAPI in the cell
chamber were imaged by z-stack confocal microscopy (Zeiss LSM
710). Then, the Cell Counter plugin of Fiji ImageJ was used to
manually count the cells as the automated counter was not able to
distinguish cells accurately in 3D. This process was repeated in
triplicates and a best estimate of the average cell number (9,812 ±
838 cells) in the liver MPS was used to normalize albumin and
urea secretion per cell.
Live/Dead Assays
To assess viability of hiPSC-Heps in the liver MPS, the LIVE/
DEAD Cell Imaging Kit from Molecular Probes (R37601) was
used. Viable cells were stained with green-fluorescent calcein AM
(488 nm) and dead cells with red ethidium homodimer-1
(570 nm). The liver MPS was rinsed with PBS and 60 μL of
dye were added via the media channel and incubated for 20 min.
Images were collected using an inverted Nikon TE300
microscope with a Lumencore Spectra X light engine. Images
were processed with Fiji ImageJ. Counts of live or dead cells were
obtained using a segmentation analysis coupled to a constant area
exclusion filter. For long-term culture, the liver MPS was
incubated at 37°C and fed by a New Era NE-1800 syringe
pump with continuous media flow (10 μL/h). For visual
characterization, the cells were imaged using a brightfield
phase contrast daily without detachment from the syringe
pump using a Nikon Eclipse TE300 microscope.
Efflux Media Collection and Biochemical
Measurements in Liver Microphysiological
System
Perfusion of the liver MPS was initiated 2 days after loading to
allow recovery and spreading of the hiPSC-Heps. Media was
collected every two days and analyzed for albumin and urea
secretion. Albumin was measured using an enzyme-linked
immunosorbent assay (Bethyl Laboratories). Urea nitrogen was
measured using a colorimetric assay (urea nitrogen test, Stanbio
Laboratory) modified to be performed in a 384-well microtiter
plate, including increase in the incubation time of reactants from
60 to 90 min at 60°C prior to reading. All the biochemical assays
were performed in 10 µL of media andmeasured on a SpectraMax
i3 plate reader (Molecular Devices). All the sample results were
calculated by interpolation of sample raw values from standard
curves performed in parallel. The same assays were repeated for
conventional cell cultures of hiPSC-Heps.
Drug Metabolism of Human Induced
Pluripotent Stem Cell-Heps in Conventional
Cell Culture and Liver Microphysiological
System
For drug metabolism study in conventional cell culture, hiPSC-Heps
were incubated with 1 or 10 µM of cisapride (Sigma) inWilliams’ E +
Cocktail B (see below) with or without 10 µM ketoconazole (Sigma)
for the indicated time-points (from 30min to 24 h) at 37°C in an
incubator. Then the dosing solution was collected, the cells were
washed three times with ice-cold PBS, and harvested for further drug
analysis by mass spectrometry (see “Drug Metabolism
Measurements” section). To determine CYP3A4 activity and its
inhibition by ketoconazole in the liver MPS after day 25, a
luminescence assay (P450GLo, Promega) was used. Briefly, the
liver MPS was incubated with luciferin-PFBE for 24 h, after which
the supernatant was transferred to a 96-well plate and the luciferin
detection reagent was added to initiate a luminescent reaction. The
plate was then incubated for 20min at RT to complete the reaction.
Luminescence levels were measured on a SpectraMax i3 plate reader.
CYP3A4-mediated metabolism of cisapride was performed in
Williams’ E + Cocktail B. Media was supplemented with 100 nM
and 1,000 nM cisapride and perfused through the liver MPS on
differentiation day 26. These concentrations were subsequently
corrected for the absorption into PDMS (see “Drug Absorption to
Polydimethylsiloxane” section). Efflux media was collected over a 24-
h period and stored at −80°C for further analysis by mass
spectrometry (see “Drug Metabolism Measurements” section).
Drug Metabolism Measurements
The cisapride drug and norcisapride metabolite were extracted
from efflux media and analyzed using a Shimadzu UFLC system
(Carlsbad) coupled with a Sciex API5000 triple quadrupole mass-
spectrometer (Foster City) using positive ionization mode.
Cisapride and norcisapride were further separated by a gradient
mode of 10 mM ammonium acetate–acetonitrile as a mobile phase
using an Acclaim Trinity P1 reverse phase column (2.1 × 50mm,
3 μm; Thermo Fisher Scientific). Mass ion transitions (Q1/Q3) of
cisapride and norcisapride were m/z 468.3/186.0 and m/z 314.2/
184.0, respectively. 1-naphthol, 1-naphthol-s-glucuronide,
p-nitrophenol, and p-nitrophenol sulfate were separated by a
gradient elution with 0.1% formic acid in H2O and 0.1% formic
acid in acetonitrile as mobile phases using a XTerraMSC18 reverse
phase column (4.6 × 50mm, 3 μm; Waters). Mass ion transitions
of 1-naphthol, 1-naphthol-s-glucuronide, p-nitrophenol, and
p-nitrophenol sulfate were m/z 143.3/115.3, m/z 318.9/143.3,
m/z 138.2/168.1, and m/z 217.9/138.2, respectively. The
standard curve range of each drug and metabolite was
0.5–2,000 nM. Precision (defined by the coefficient of variation)
and accuracy (defined by relative error) of LC-MS/MS analyses
were both <15% for all drugs and metabolites.
EC50 Studies of Cisapride on the Cardiac
Microphysiological System
Culture medium for the cardiac MPS was RPMI 1640 medium
(11,875–093; Gibco) supplemented with B-27 (17,504–044;
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Gibco). The cardiac MPS was fabricated as described in
previous studies (see Supplementary Material) (Mathur
et al., 2015; Huebsch et al., 2018). Detailed characterization
of the cardiac MPS including gene profiling, flow cytometry,
immunofluorescence, and computational analysis of ion
channels has been performed (Mathur et al., 2015; Huebsch
et al., 2018; Tveito et al., 2018; Jæger et al., 2019). For all
pharmacology, the cardiac MPS was first equilibrated to
phenol red–free Williams’ E media + Cocktail B (see below)
containing vehicle control (DMSO or water, to a final
concentration of 0.1% v/v). On the day of the experiment,
the freshly measured cisapride drug was dissolved into DMSO.
After the initial baseline recording in vehicle control
condition, media was exchanged for the lowest cisapride
drug dose, and the cardiac MPS was incubated for 30 min
at 37°C. Media changes during the drug testing were either
performed manually (Huebsch et al., 2018) or using an
automated Fluigent pump system (Fluigent, N. Chelmsford,
United States). A volume flow of 30 μL/min was applied for
5 min to change to a new drug dose followed by 15 μL/min
continuous perfusion. Spontaneous beating activity was
recorded via brightfield microscopy. Optical measurement
of action potential in the cardiac MPS was performed using
the voltage-sensitive dye Berkeley Red Sensor of
Transmembrane potential (BeRST-1; Supplementary Figure
S1A) (Huang et al., 2015). BeRST-1 is a far-red to near-
infrared dye that changes fluorescence intensity in response
to membrane voltage changes through a photo-induced
electron transfer mechanism. BeRST-1 dye was synthesized
and its purity verified as previously described (Huang et al.,
2015). For action potential recording, cardiac MPS was first
labeled overnight with 2.5 µM BeRST-1. For the cardiac MPS
metrics analysis, the beat rate–corrected action potential
durations at 30, 80, and 90% repolarization (cAPD30,
cAPD80, and cAPD90; Supplementary Figure S1B) were used.
Cisapride and Ketoconazole Drug–Drug
Interaction Testing in Liver and Cardiac
Microphysiological Systems
We used “functional coupling” for the DDI studies, where the
media was first exposed to the liver MPS, collected, and then
exposed to the cardiac MPS. Functional coupling of the liver and
cardiac MPS started with testing of the basal pHep maintenance
Williams’ Emedium in the cardiac MPS to determine its effect on
electrophysiology and toxicity in hiPSC-derived cardiomyocytes
prior to DDI studies. Williams’ E medium was supplemented
with Gibco Cell Maintenance Supplement Pack B (Cocktail B;
Thermofisher Scientific), which contains bovine serum albumin
(5.35 μg/ml) as a carrier protein and other supplements such as
ITS that support pHep culture. Dexamethasone was not included
to exclude likely confounding effects on hiPSC-derived
cardiomyocytes.
For the DDI experiment, first the liver MPS was exposed to
cisapride (50–100 nM) in Williams’ E basal media + Cocktail B
with or without ketoconazole (10 μM) for 8 h at 37°C. The efflux
was collected from the media port after passing through the liver
MPS and stored at −20°C. Next, the cardiac MPS was equilibrated
with phenol red–free Williams’ E media + Cocktail B containing
vehicle control (DMSO to a final concentration of 0.1% v/v). After
the initial APD baseline recording while exposed to the vehicle
control, the cardiacMPS was exposed to the thawed effluxmedia for
30 min at 37°C, followed by APDmeasurements as described below.
Cardiac Microphysiological System
Imaging and Analysis
All the images were collected using a Nikon Eclipse TE 300
microscope. The brightfield videos were analyzed for beating
physiology using an updated version of our open-source motion-
tracking software (Huebsch et al., 2015). The software can be
downloaded at https://sites.wustl.edu/huebschlab/resources/.
Microscopy files were directly read into the MATLAB-based
graphical user interface (GUI), and the contractile motion was
analyzed via an exhaustive-search block-matching optical flow
algorithm that compared the position of 8 × 8 pixel macroblocks
at frame i to their position at frame i+5 (corresponding to the
motion in 50 msec). Motion vectors were used to calculate beat
rate. BeRST-1 data were quantified using in-house MATLAB
code that was developed based on previous work by Laughner
et al. (2012) and Boggess et al. (2019). BeRST-1 videos were
analyzed for beat rate and 80 and 90% action potential duration
(APD80, APD90), using custom MATLAB and Python scripts.
Characterization of Drug Absorption into
Polydimethylsiloxane
While PDMS is widely used to build microfluidic devices, due to
its biocompatibility and convenience for microfabrication, the
material has the disadvantage that it can absorb small molecules
with low LogP values (van Meer et al., 2017; Halldorsson et al.,
2015). Thus, absorption of cisapride to PDMS was characterized
to correct the dosages used in the experiments. The dose
escalation studies were first repeated in the liver MPS, without
cells, to model the drug analysis. Using LC-MS/MS, ion
abundances of the drug in stock samples and in efflux media
were measured to calculate the percent remaining. One device
was used per escalation study of 10, 50, 100, 500, and 1,000 nM,
and the average percent remaining were 35.52, 30.54, 30.95, 34.55,
and 39.79 nM, respectively (Supplementary Figure S2). For the
drug response studies, the cisapride concentration was corrected
for PDMS drug absorption (60–70%) (Shirure and George, 2017;
van Meer et al., 2017).
Details for the drug absorption measurements follow.
Assembled liver and cardiac MPS chips were placed on a
temperature-controlled glass base (Thermo Plate; Tokai Hit) to
maintain the temperature of the chips at approximately 37°C. The
drug cisapride was prepared to the concentrations of 5, 10, 50,
and 100 nM in Williams’ E medium supplemented with Cocktail
B. The MPSs were loaded with 100 μL of drug solution via a
pipette tip at the media inlet port and an empty pipette tip placed
at the media outlet. Flow at the media channel was induced due to
the difference in hydrostatic pressure head at the inlet and the
outlet. For a given concentration of drug, the system was given
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30 min after loading before the pipette tip at the inlet was taken
out and the solution in the device and at the outlet tip was
collected. Experiments were started with the lowest concentration
(i.e., 5 nM) and dose concentration was increased for subsequent
experiments (i.e., dose escalation). Technical replicates for each
drug concentration are indicative of solutions collected from
different devices. Drug solutions collected from devices were
diluted by half using a 10 nM solution of propranolol used as
an internal standard for LC-MS/MS. Standards of cisapride drug
with propranolol as internal control were also prepared. Samples
were analyzed using an LC system (1200 series; Agilent)
connected in line with an LTQ-Orbitrap-XL MS equipped
with an electrospray ionization source and operated in the
positive ion mode (ThermoFisher Scientific). The LC was
equipped with a reversed-phase analytical column (length:
150 mm, inner diameter: 1.0 mm, particle size: 5 μm; Viva
C18; Restek). Acetonitrile, formic acid (Optima LC-MS grade,
99.5+%; Fisher), and water purified to a resistivity of 18.2 MΩ cm
(at 25°C) using a Milli-Q Gradient ultrapure water purification
system (Millipore) were used to prepare mobile phase solvents.
Data acquisition and processing were performed using Xcalibur
software (version 2.0.7, ThermoFisher Scientific). Processed data
were used to quantify the amount of drug lost due to absorption
in the PDMS-based MPSs via comparison with the drug
standards.
Statistical Analysis
Differences in drug and control population measurements
reported as significant have a p < 0.05, as determined by the
application of a t-test with the assumption of equal variance.
Direct comparisons were made by nonpaired Student’s t test and
for multiple comparisons ANOVA was used. All curve fitting was
done using GraphPad Prism 6.
RESULTS
Directed Differentiation of Human Induced
Pluripotent Stem Cell-Heps
Directed differentiation of hiPSCs into hiPSC-Heps was
performed in 2D cell culture using an optimized protocol
(Figure 1A; see Material and Methods for details).
Brightfield microscopy showed characteristic morphological
changes occurring during the differentiation process
(Figure 1B) from hiPSCs (day 0) to definitive endoderm
(day 8), liver progenitors (day 13), immature (day 18), and
mature hepatocytes (day 23). Immunofluorescence showed
lack of the pluripotency marker OCT3/4 past the hiPSC
stage (Figure 1B); hepatic nuclear factor 4 alpha (HNF4A)
started to be expressed at day 13 when cells committed to
hepatic fate; alpha-fetoprotein (AFP) stained strongly positive
in immature hepatocytes at day 18; and albumin (ALB) was
only detectable at the final stage of differentiation (day 23). At
this stage, 88.4% of cells expressed albumin and 32.7% were
positive for asialoglycoprotein receptor 1 (ASGR1), a marker
of mature hepatocytes, in flow cytometry (Figure 1C and
Supplementary Figure S3).
Characterization of Drug Metabolism in
Human Induced Pluripotent Stem Cell-Heps
A prerequisite for drug metabolism studies is sufficient cellular
uptake of the drug as well as efflux of the metabolites. Therefore,
activities of three uptake (Figure 1D) and two efflux (Figure 1E)
transporters were measured by high-performance liquid
chromatography coupled with tandem mass spectrometry
(LC-MS/MS) using drug/inhibitor combinations. For the
uptake transporter studies, hiPSC-Heps were exposed to a
specific drug internalized by the transporter, with or without
a specific inhibitor of the transporter—activity of organic anion
transporters (OATs) was tested with acyclovir/probenecid,
organic cation transporters (OCTs) with metformin/
decynium-22, and organic anion transporting polypeptides
(OATPs) with rosuvastatin/rifamycin-SV. Metabolism-
qualified pHeps were used as controls. All the three phase 0
uptake transporters were active in hiPSC-Heps and pHeps,
including responsiveness to specific inhibitors (Figure 1D).
Next, the activities of two phase III efflux transporters were
analyzed using substrate/inhibitor challenge. The
P-glycoprotein (P-gp) was tested with the substrate digoxin
and the breast cancer resistance protein (BCRP) with
mitoxantrone. Both efflux transporters were active in hiPSC-
Heps and pHeps, including responsiveness to the P-gp/BCRP
inhibitor GG918 (Figure 1E). To further assess whether our
hiPSC-Heps allowed studies of phase I drug metabolism, we
measured the activity of key hepatic CYP enzymes (Figure 1F).
Based on a luminescence assay, CYP3A4 was one of the most
active drug-metabolizing CYPs in hiPSC-Heps and its activity
was in the range of 3–5% of pHeps (Figure 1F). Activities of
other CYPs were 2–3 orders of magnitude lower in hiPSC-Heps
than in pHeps (Figure 1F), which was confirmed by gene
expression analysis (Figure 1G) and indicated some lack of
maturation of our hiPSC-Heps compared to pHeps. However,
relatively high CYP3A4 activity suggested maturation beyond
the fetal hepatocyte stage since CYP3A4 is not expressed in
fetuses and neonates (Tréluyer et al., 2001). Finally, the activities
of the phase II conjugating enzymes UDP-
glucuronosyltransferases (UGTs) and sulfotransferases
(SULTs) were in the range of 1–10% of pHeps, as shown by
LC-MS/MS using the substrate/metabolite combination 1-
naphtol/naphtol-s-glucuronide and nitrophenol/nitrophenol-
sulfate, respectively (Figure 1H). In summary, our optimized
protocol produced hiPSC-Heps capable of all phases of drug
metabolism, although some transporter and enzyme activities
were underdeveloped. This finding accords with findings made
with other protocols for hiPSC-Hep differentiation and
underscores the importance of in-depth characterization of
these cells to ascertain suitability for the intended experiments.
Development of the Liver
Microphysiological System
The liver MPS was designed to mimic a single acinus, the smallest
functional unit of the liver, which comprises three different zones,
exposing hepatocytes to different concentrations of nutrients and
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oxygen (Figure 2A). Our chip design was a cylindrical-like
structure that was cut in half and laid flat, thus creating two
rectilinear chambers—one chamber for the hiPSC-Heps and one
chamber for media to mimic the sinusoid. The chambers were
separated by an isoporous polyethylene terephthalate (PET)
membrane with 3 µm pores that acted as a diffusive barrier,
mimicking the function of the liver sinusoidal endothelial cells
that protect the hepatocytes from the shear stress forces of the
FIGURE 1 | Differentiation and characterization of hiPSC-Heps. (A) Schematic of the hiPSC-Hep differentiation protocol. The arrows show cells at different stages
progressing from hiPSCs (day 0) to mature hepatocytes (day 23). Growth factors and small molecules are listed inside the arrows. (B) Brightfield and immunofluorescent
images matching the differentiation stages in (A). Nuclei were stained with DAPI. Scale bars, 100 µm. (C) Flow cytometry shows percentage of hiPSC-Heps expressing
albumin and ASGR1 at day 23. (D) Activity analysis of uptake transporters by inhibition with specific inhibitors. Results obtained without inhibitors were set to 100%
to display transporter activity as decrease of drug concentration in the cells. Data are presented as the mean ± standard deviation from three to four (hiPSC-Heps) or two
to three (pHeps) independent experiments. (E) Activity analysis of efflux transporters by inhibition with specific inhibitors. Results obtained without inhibitors were set to
100% to display transporter activity as increase of drug concentration in the cells. Data are presented as the mean ± standard deviation from four to five (hiPSC-Heps)
and three (pHeps) independent experiments. (F) Activity analysis of CYPs. Data are presented as the mean ± standard error of the mean from three (hiPSC-Heps) or two
(pHeps) independent experiments. (G)Quantitative reverse transcription PCR analysis of CYP genes. (H) Activity analysis of conjugating enzymes. Data are presented as
the mean ± standard deviation from two (UGTs, SULTs; pHeps), three (UGTs; hiPSC-Heps), or five (SULTs; hiPSC-Heps) independent experiments.
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FIGURE 2 | Design, characterization, fabrication, and testing of liver MPS. (A) Illustration showing the liver acinus as the basic building block of the liver inspiring the
liver MPS design. (B)COMSOL® simulation results. Small concentration gradients with physiologically relevant oxygen levels are observed when cells in the cell chamber
consume oxygen and oxygen diffuses from the ambient through the PDMS roof and walls (left). When oxygen is not diffused through the PDMS cells become hypoxic
after 300 s (center). The hiPSC-Heps OCR used in the simulations was determined from Seahorse measurements. The oxygen concentration jumps between
media channel and cell chamber are due to diffusion across the porous membrane. A dilute solution containing a small molecule entering the media channel at 20 μL/h
diffuses across the porous membrane into the cell chamber and reaches a uniform concentration within the liver MPS within 300 s (right). Simulation assumes
impermeable walls and no cell consumption. (C) Preparation and microfabrication steps of the liver MPS. (D) Photograph of a ready-to-use liver MPS. The catheter
couplers link the tubes and microfluidic channels for perfusion. The short plug in the middle keeps the loaded cells in the chamber. (E) Schematic of the liver MPS that
shows the localization of the cell chamber; the red arrows indicate the inlet and the outlet of the media channels, whereas the black arrow marks the inlet of the cell
chamber. High cell viability in the tissue chamber after loading is demonstrated by fluorescence imaging of acetoxymethyl calcein (calcein-AM; live cells labeled green)
and ethidium homodimer (dead cells labeled red). (F) Immunofluorescent images of hiPSC-Heps seven days after loading into the liver MPS.
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blood flow. Prodanov et al. used a similar approach with pHeps
and two additional cell lines to model contributions from
endothelial cells and hepatic stellate cells (Prodanov et al.,
2016). Our system used only hiPSC-Heps and relied on a
different fluidic design to minimize shear stress within the
hiPSC-Hep chamber, thereby reducing potential cell damage.
Additionally, our liver MPS was designed to allow loading of a
higher number of cells by centrifugation to improve 3D liver
tissue formation and metabolic function.
Oxygen consumption was an important factor in designing the
liver MPS since hepatocytes have particularly high oxygen
consumption rates (OCRs) (Kidambi et al., 2009). The
performance of the liver MPS was simulated and optimized
in silico using computational modeling (Figure 2B; see
Material and Methods for details). To maintain a high oxygen
level in different flow conditions, the liver MPS was fabricated
using a gas-permeable polydimethylsiloxane (PDMS). OCR in
adult hepatocytes ranges from 0.3 to 0.9 nmol/s/106 cells
(Kidambi et al., 2009), which is an order of magnitude higher
than ∼0.034 nmol/s/106 in HepG2 cells (Provin et al., 2009;
Mishra and Starly, 2009). The OCR in our hiPSC-Heps,
measured using the Seahorse flux analyzer, was 0.1 nmol/s/106
cells (Supplementary Figure S4), which is consistent with
previously reported results (Mun et al., 2019). Using
computational simulations, a media and cell chamber
combination was designed that allowed for physiologically
relevant oxygen levels in the cell chamber when considering
the OCR of hiPSC-Heps and oxygen diffusion from the
ambient through the PDMS walls. Using the OCR measured
for our hiPSC-Heps, simulation showed a steady oxygen level of
0.16 mol/m3 across the device similar to the periportal region
(pO2 0.10–0.12 mol/m3 or 60–70 mmHg) (Allen and Bhatia,
2003) after 24 h (Figure 2B, left). This tissue-level oxygen
consumption is close to the physiological range and lower
than hyperoxia (<160 mmHg) (Marconi et al., 2014).
Additional simulation assuming no oxygen diffusion through
the PDMS showed oxygen depletion in the device after 300 s due
to the cells’ high OCR (Figure 2B, center). Shear stress, which is
determined by the media flow rate used in the device, was lower
than 5 dyn/cm2 previously found to diminish albumin and urea
synthesis in rat pHeps (Park et al., 2005; Tilles et al., 2001). To
give detail on the oxygen flux assumptions used in the simulation,
additional COMSOL® modeling information on the mesh and
computational domains of liver MPS used are provided in
Supplementary Figure S5. In our optimal design, it took an
estimated 300 s using a 20-μL/h flow rate for a small molecule to
reach a uniform concentration inside an empty device accounting
for diffusion of the drug across the membrane into the cell
chamber (Figure 2B, right).
Fabrication of the liver MPS multilayer device was achieved
with four parts: a glass slide, two layers of PDMS patterned with
media and cell chambers, and a PET membrane. Media and cell
chambers were permanently bonded into a device using oxygen
plasma treatment and silanization for the PETmembrane (Loskill
et al., 2017) (Figure 2C), creating the final liver MPS (Figure 2D).
The 3D liver microtissue in the MPS had a thickness of 80 μm
covering the entire cell chamber of 5,560 μm (length) × 560 μm
(width) in dimension. The liver MPS design permitted high cell
viability after loading, indicated by live-dead staining of the cell
chamber (Figure 2E). Cellular function in the device was further
confirmed by visualization of nuclear morphology, density, and
distribution of hiPSC-Heps, ALB and AFP expression, and
formation of bile canaliculi (Figure 2F and Supplementary
Figure S6). These assays showed that hiPSC-Heps were viable
and maintained hepatocyte differentiation over 2 weeks of culture
in the liver MPS.
Comparison of Synthetic Function of
Human Induced Pluripotent Stem Cell-Heps
in Liver Microphysiological System and
Conventional Cell Culture
Potential differences in differentiation and function between
hiPSC-Heps in the 3D environment of the liver MPS and under
2D conditions in conventional cell culture dishes were assessed
by the analysis of albumin and urea secretion into the media.
For this, hiPSC-Heps were released from the original
differentiation cell cultures, split, and either seeded into
devices or replated on cell culture dishes. At the end of a 9-
day time course, hiPSC-Heps secreted 41.41 ± 3.53 µg/106
cells/day albumin in the device, compared to 12.47 ±
0.53 µg/106 cells/day in conventional culture (Student’s
t test, p  0.0036), a more than three-fold increase
(Figure 3A). Similarly, hiPSC-Heps secreted 49.75 ±
5.04 µg/106 cells/day urea in the device, compared to 7.37 ±
1.12 µg/106 cells/day in conventional culture (Student’s
t test, p  0.0009), a seven-fold increase (Figure 3B). These
results show that the liver MPS improves the synthetic
function of hiPSC-Heps as compared with conventional cell
culture.
Comparison of Human Induced Pluripotent
Stem Cell-Hep–Mediated Cisapride
Metabolism in Liver Microphysiological
System and Conventional Cell Culture
The arrhythmogenic drug cisapride is converted in pHeps into
non-arrhythmogenic norcisapride ((Pearce et al., 2001) by
CYP3A4 (Meuldermans et al., 1988; Bohets et al., 2000))
(Figure 4A). Therefore, the metabolism of cisapride can be
inhibited or reduced by drugs and foods that act as CYP3A4
inhibitors such as ketoconazole or grapefruit (Figure 4A).
Cisapride metabolism in hiPSC-Heps was assessed in
conventional 2D cell culture using mass spectrometry to
measure norcisapride formation within 30 min after the
addition of 1 or 10 μM of the parental drug to the cells.
Intra- and extracellular amounts of norcisapride were
measured and put in relation to the cisapride input
concentration and the time the cells were exposed to the
drug, allowing the calculation of the metabolite formation
clearance. Relative metabolite formation clearance for 1 μM
of cisapride (100% +/− 10.81) was significantly reduced by the
addition of 10 µM of ketoconazole to 34.87% +/− 28.04
(Figure 4B). Likewise, relative metabolite formation
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clearance for 10 μM of cisapride (100% +/− 6.08) was
significantly reduced by the addition of 10 µM of
ketoconazole to 35.18% +/− 16.55 (Figure 4B). To
determine the ability of hiPSC-Heps to metabolize cisapride
over an extended period of time, the percentage of cisapride
converted into norcisapride was calculated 3, 6, and 24 h after
adding 1 μM of cisapride to the cells—without CYP3A4
inhibition by 10 µM of ketoconazole, 2.66% ± 0.92, 6.19% ±
0.69, and 9.33% ± 0.23 of cisapride were metabolized, which
dropped to 0.85% ± 0.02, 0.99% ± 0.06, and 2.87% ± 0.97 with
ketoconazole, that is, a reduction by 68, 85, and 70%,
respectively (Figure 4C).
Next, the hiPSC-Hep-mediated cisapride metabolism was
analyzed in the liver MPS. First, a nondestructive luminescence
assay (Promega P450-Glo; the same assay that was used in
Figure 1F in 2D hiPSC-Heps)—allowing serial analysis of
samples taken from the media channel—was used to assess
CYP3A4 activity based on the cleavage-mediated activation of a
luciferin substrate. As expected, additional infusion of 10 µM of
ketoconazole into the device caused a seven-fold decrease in
relative luminescence units (RLU) (2,640 ± 247 RLU vs. 361 ±
13 RLU; Student’s t test, p  0.0008) (Figure 4D). Second, mass
spectrometry was used to compare cisapride metabolism between
hiPSC-Heps in the liver MPS or in conventional cell culture, which
showed that cisapride concentrations were similarly reduced under
both culture conditions 12 h after exposure to 100 nM of the drug
(Figure 4E). These results establish that the small media volumes
of the liver MPS are sufficient for luminescence assays and mass
spectrometry, and that CYP3A4-mediated cisapride metabolism is
maintained in hiPSC-Heps transferred into the device.
Drug–Drug Interaction Studies in Integrated
Liver and Cardiac Microphysiological
Systems
Before integration of liver MPS and cardiac MPS, cisapride-
induced changes in beat rate and electrophysiology were
analyzed in the cardiac MPS, which was created as previously
described, including cardiomyocyte generation from the same
hiPSC line used to generate hiPSC-Heps (Mathur et al., 2015;
Huebsch et al., 2018). In the clinical setting, the QT interval is
used as a measure of cardiac electrophysiology. Since the QT
interval depends largely on the heart rate, it is typically reported
as QTc, a value normalized for 60 beats per minute (BPM) using
Fridericia’s formula to introduce the heart rate correction
(Fridericia, 1920; Fridericia, 2003). Using similarly corrected
action potential duration at 80% of the repolarization
(cAPD80) as a surrogate for QTc, an EC50  9.63 nM was
observed in the cardiac MPS for cisapride concentrations
ranging from 0 to 180 nM (after the correction for absorption
into the PDMS of the device) (Figure 5A). Beyond 180 nM, data
became dispersed and eventually cAPD80 values decreased,
indicating toxic effects at the highest drug doses
(Supplementary Figure S7A). We also investigated
triangulation, a metric that characterizes disturbances of the
repolarization and more accurately identifies proarrhythmic
substrates (Hondeghem, 2008). An increase in the
triangulation metric, which we calculated as
(cAPD80–cAPD30)/cAPD80, indicated a shift from rectangular
to more triangular beat shape, associated with arrhythmia risks
(Hondeghem et al., 2001). We found a strong dose-dependent
increase in triangulation values in response to cisapride with
significant changes at 36 nM and higher (Figure 5B). Exposure of
the cardiac MPS to 17 nM of cisapride caused a statistically
significant prolongation of the cAPD (Figure 5C). Beat rate
was significantly elevated only at extremely high cisapride
concentrations (Supplementary Figure S7B).
To facilitate the DDI study of cisapride and ketoconazole, and
its effects on cardiac function, the liver and cardiac MPSs were
integrated by functional coupling. A prerequisite was to use a
common culture medium that supported the function of both
hiPSC-Heps and hiPSC-derived cardiomyocytes in their
respective devices. Literature reports on common media
compositions for liver and cardiac tissues vary greatly (Oleaga
FIGURE 3 | Synthetic function of hiPSC-Heps in conventional cell culture and liver MPS. (A) Albumin secretion into the media measured on the indicated days after
seeding hiPSC-Heps into the liver MPS or replating them on conventional cell culture dishes (2D). Data are presented as the mean ± standard error of mean for five (liver
MPS) and three (2D) independent experiments. Unpaired Student’s t test with equal standard deviation, **p < 0.05, ***p < 0.01. (B) Urea secretion into the media
measured on the indicated days after seeding hiPSC-Heps into the liver MPS or replating them on conventional cell culture dishes. Data are presented as the
mean ± standard error of mean for three independent experiments. Unpaired t-test with equal standard deviation, ***p < 0.01.
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et al., 2018; Zhang et al., 2017; Oleaga et al., 2016) and typically
suitability for both tissues is verified by simple viability assays. In
our work, we used the liver media for drug testing, which ensured
ideal and consistent conditions for all liver data. To verify
compatibility with the cardiac chip, we demonstrated that the
beat rate was not altered in response to the commonmedia, which
was a more stringent and functionally relevant criterion than cell
viability. Baseline beat rate was indistinguishable in RPMI plus
B27-supplement or after a 30-min incubation in Williams’ E +
Cocktail B media (Supplementary Figure S8). For DDI studies,
cardiac MPSs were incubated with Williams’ E + Cocktail B
media for 30 min and baseline cAPD90 values were recorded and
normalized for each device. Next, the efflux from the liver MPS
was introduced into the cardiac MPS via its media ports. The
FIGURE 4 |Cisapride metabolism in hiPSC-Heps in conventional cell culture and liver MPS. (A)Metabolism of the arrhythmogenic drug cisapride into norcisapride
by CYP3A4 in the liver (top). Drug–drug or drug–food interactions can inhibit this metabolic reaction. Ketoconazole (Keto) inhibits CYP3A4-driven metabolism of
cisapride into norcisapride (bottom). (B) Relative metabolite formation clearance for cisapride in hiPSC-Heps in conventional cell culture within 30 min. Data are
presented as the mean ± standard deviation from three independent experiments with two biological replicates each. Unpaired Student’s t test, ***p < 0.0003,
****p < 0.0001. Experiments were performed in cell culture dishes with low drug absorption. (C) Percentage of cisapride metabolized to norcisapride with and without
ketoconazole. Data are presented as the mean ± standard error of mean for two biological replicates of one experiment. The experiment was performed in cell culture
dishes with low drug absorption. (D) CYP3A4 activity in the liver MPS measured with a luminescence assay with and without ketoconazole. Data are presented as the
mean ± standard error of mean for three independent experiments. (E) Change in cisapride concentration in the liver MPS media channel and the supernatant of
conventional cell cultures (2D). Data are presented as the mean ± standard error of mean for three independent experiments.
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cAPD90 in the cardiac MPSs was not altered by efflux media from
the liver MPSs perfused with 17 nM of cisapride for 8 h. However,
efflux media from liver MPSs perfused with 17 nM cisapride
together with 10 µM of ketoconazole for 8 h significantly
prolonged the cAPD90 in cardiac MPSs (Figure 5D). These
results reproduce with functionally coupled hiPSC-derived
liver and cardiac MPSs in vitro the clinically observed DDI
between cisapride and ketoconazole (Michalets and Williams,
2000; Wysowski et al., 2001; Paakkari, 2002; Shah, 2002).
DISCUSSION
This work focused on developing a functional liver MPS
constructed from hiPSC-Heps, and using the system to study
DDI-mediated inter-organ toxicity in a liver—cardiac MPS.
There are two major reasons for creating better in vitro models
of human hepatotoxicity and liver diseases that address the “fit for
purpose” criteria used in the pharmaceutical industry. First, earlier
and accurate safety profiling of a larger number of compounds, but
still high throughput, can eliminate false-positive attrition. The
second is for testing of more challenging hepatotoxicity
mechanisms and complex disease models over longer time
periods with high content models representing physiologically
relevant fluid flow and cell types (Hewitt et al., 2007; Song
et al., 2009; Godoy et al., 2013; Soldatow et al., 2013). Focusing
on the latter, we created a liver MPS employing hiPSC-Heps that
provides a virtually unlimited source of patient-specific cells. In-
depth characterization of hiPSC-Heps generated with the
optimized differentiation protocol showed that levels of drug
uptake, metabolism, and efflux were inferior to pHeps, but
sufficient for use in drug screening and toxicity studies.
Microfabrication and microfluidic technologies provide a
microenvironment that resembles in vivo conditions more
closely than conventional cell culture (Dittrich and Manz,
2006; Sung and Shuler, 2010). For example, in multiwell plates
FIGURE 5 | Cisapride effects on cardiac MPS and DDI in integrated liver and cardiac MPSs. (A) Cisapride-induced changes in cAPD80 in the cardiac MPS.
Nonlinear regression fit log(inhibitor) vs. response (Hill Equation using three parameters) was used to obtain EC50 value (9.63 nM, gray vertical line). Cisapride values were
corrected for PDMS drug absorption of 64%. Statistical differences are based on one-way ANOVA (p values: *  0.0259 and **  0.0095). (B)Cisapride-induced changes
in beat shape plotted as triangulation value (cAPD80 - cAPD30)/cAPD80. Cisapride values are corrected for PDMS drug absorption of 64%. Statistical differences are
based on one-way ANOVA (p values: *  0.0174, **  0.048, ***  0.0004 and **** <0.0001). (C) Effect of increasing concentrations of cisapride on cAPD90 in the cardiac
MPS. The cAPD90 values of the treatments were normalized to the respective values for vehicle controls. Data are presented as the mean ± standard error of mean for at
least six independent experiments. Ordinary one-way ANOVA with Dunnett’s correction for multiple comparisons test, ***p < 0.0001. Cisapride values are corrected for
PDMS drug absorption of 64%. (D) Effect of cisapride metabolized in liver MPS on cAPD90 in cardiac MPS. cAPD90 values of the treatments were normalized to the 0 nM
control values. Data are presented as the mean ± standard error of mean for three experiments. Unpaired Student’s t test with equal standard deviation was used, *p <
0.05. Cisapride values are corrected for PDMS drug absorption of 64%.
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and culture flasks hepatocytes are cultured in monolayers with
excessive medium volume-to-cell number ratios. More
physiological medium-to-cell ratios can be achieved by using
the small system volumes of microfluidic devices (Khetani and
Bhatia, 2008; Dash et al., 2009), which preserves the efficacy of
low-concentration autocrine and paracrine signals, including
secreted molecules, growth factors, matrices, and hormones
(Abhyankar et al., 2006). Along these lines, the
microfabricated liver MPS described in this study can be used
under a controlled range of flow rates, providing flexibility for
optimizing cell viability and function. Using a PET membrane to
mimic an endothelial cell barrier, we protected the cells from
flow-induced shear stress, which can compromise viability (Tilles
et al., 2001; Park et al., 2008; Vinci et al., 2011). Moreover, under
low shear stress conditions, perfusion/flow cultures provide better
function of hepatocytes than static cultures, presumably due to
greater nutrient exchange (Albert et al., 2007). Other factors
promoting function of hiPSC-Heps in the device include direct
3D cell–cell contact and the low ratio of medium-to-cell volume.
Whether a small subset of hiPSCs not committing to hepatocyte
differentiation, but giving rise to mesenchymal cell types instead
(data not shown), further aided hiPSC-Hep function remains to
be determined (Bhatia et al., 1999). Currently, cross-laboratory
studies are ongoing for performance evaluation of our MPSs
compared with other hiPSC-based models.
Our liver–cardiac MPS successfully replicated a highly
publicized example of DDI, severely impacting human health
despite successful clinical trials. Cisapride, a prokinetic used to
treat gastroesophageal reflux (Wiseman and Faulds, 1994), caused
prolongation of the QT interval, ventricular arrhythmias, and
torsade de pointes (Wysowski and Bacsanyi, 1996; Wysowski
et al., 2001), particularly if metabolism of the drug was
impaired (Wiseman and Faulds, 1994; Shah, 2002). In humans,
cisapride is extensively metabolized to inactive norcisapride
through N-dealkylation (41–45% of the administered dose) and
to several minor metabolites (Meuldermans et al., 1988). CYP3A4
is involved in the metabolism of most drugs in the human liver,
including cisapride N-dealkylation (Shimada et al., 1996; Pearce
et al., 2001; Hyland et al., 2003). By 2007, DDI with ketoconazole
leading to inhibition of CYP3A4 or other risk factors caused 300
deaths and 16,000 cardiac injuries, ultimately leading to the
voluntary removal of cisapride from the market (Comeau, 2007).
We used this example to demonstrate the robustness of liver-
cardiac MPS interaction studies to predict DDI. First, we
validated the cisapride metabolism of hiPSC-Heps using LC-
MS/MS and a luminescence assay and confirmed that the
CYP3A4 metabolic function was inhibited by the addition of
ketoconazole to the media using the norcisapride metabolite as a
reference value (Supplementary Figure S9). Using the cAPD as a
proxy for the QTc interval, we confirmed cisapride-induced
cAPD prolongation in the cardiac MPS in a dose escalation
manner, and identified an EC50 of 9.63 nM. This EC50 value is
more sensitive than the previous estimates of 32 nM (Liang et al.,
2013) in 2D hiPSC-derived cardiomyocytes and 21.2 nM
(Haraguchi et al., 2015) or 20 nM (Crumb et al., 2016) in
human HEK293 cells (Supplementary Table S1). Our
investigation of arrhythmia using triangulation as a metric
correlates with the observed cAPD increase and underlines the
arrhythmogenic risk associated with cisapride. The fact that
triangulation values increase over the entire dose range while
cAPD80 values drop at the highest (toxic) doses further underlines
the robustness of triangulation as a metric for arrhythmogenic risk.
Based on the estimated therapeutic plasma concentration
(ETPC) of cisapride (2.6–4.9 nM) (Redfern et al., 2003), we
calculated a margin of safety of approximately 3.7-fold, which
is close to the clinically determined safety margin of 1.1- to 6.5-
fold (Redfern et al., 2003; Liu et al., 2006; Harris et al., 2013).
Redfern et al. (2003) have suggested that a margin of 30-fold
provides a degree of safety necessary for drugs that can cause
cardiac arrhythmias. Next, using functionally coupled liver and
cardiac MPSs, prolongation of cAPD was eliminated when
cisapride was passed through the liver MPS before exposure to
the cardiac MPS. However, when the cardiac MPS was exposed to
media from the liver MPS in the presence of cisapride and
ketoconazole, prolongation of cADP was again observed,
demonstrating the inhibitory effect ketoconazole has on the
liver metabolism of cisapride. Collectively, these data
demonstrate that the liver–cardiac MPS would have correctly
predicted cisapride’s toxic effects in the presence of ketoconazole,
potentially saving lives by indicating the need for appropriate
DDI warning.
The ability to predict DDI validates the efficacy of the
functionally coupled liver and cardiac MPSs, and illustrates how
the system can identify unforeseen DDI-induced complications,
albeit in this work retrospectively. The integrated system exhibits a
level of biological complexity that starts to approach in vivo
conditions, thereby providing a powerful platform for
simultaneously screening drug efficacy and toxicity. Although
differentiation and function of hiPSC derivatives generated with
current protocols are not equal to their primary counterparts, our
study shows that in-depth functional characterization makes it
possible to use these cells to build genetically defined faithful
multiorgan models. Furthermore, hiPSC technology allows
generation of multiorgan human disease models not attainable
with animals, opening a path for more accurate drug efficacy
analysis in real populations.
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